Valuation: Mylan Inc

Market Cap 20.03B 17.89B 16.69B 15.16B 28.53B 1,940B 28.8B 200B 78.36B 986B 75.21B 73.58B 3,170B P/E 2026 *
75.1x
P/E 2027 * 42.9x
Enterprise Value 31.98B 28.56B 26.64B 24.2B 45.54B 3,097B 45.99B 320B 125B 1,574B 120B 117B 5,062B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 2.04x
Free-Float
91.44%
Yield 2026 *
2.92%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+1.72%+38.30%+106.93% 1,043B
-0.76%-0.84%+35.21%+62.70% 618B
+0.39%+4.81%+17.81%+83.77% 481B
-0.29%-0.99%+64.79%+37.06% 351B
+1.55%+3.67%+22.07%+42.87% 338B
+1.12%+2.39%+11.72%+35.16% 269B
+1.58%+2.01%-6.43%+11.53% 244B
-1.37%+0.04%+38.29%+52.33% 220B
+0.17%-0.27%+24.40%+96.82% 182B
Average +0.56%+0.28%+27.35%+58.80% 416.3B
Weighted average by Cap. +0.38%+0.60%+30.68%+69.27%

Financials

2026 *2027 *
Net sales 14.79B 13.21B 12.32B 11.19B 21.06B 1,432B 21.26B 148B 57.85B 728B 55.53B 54.32B 2,341B 15.04B 13.43B 12.53B 11.38B 21.41B 1,456B 21.62B 150B 58.83B 740B 56.46B 55.23B 2,380B
Net income 142M 126M 118M 107M 202M 13.71B 203M 1.42B 554M 6.96B 531M 520M 22.4B 298M 266M 249M 226M 425M 28.9B 429M 2.98B 1.17B 14.69B 1.12B 1.1B 47.23B
Net Debt 11.95B 10.67B 9.96B 9.04B 17.02B 1,157B 17.18B 120B 46.75B 588B 44.87B 43.9B 1,892B 10.68B 9.54B 8.9B 8.09B 15.21B 1,035B 15.36B 107B 41.8B 526B 40.12B 39.24B 1,691B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Mylan Inc